Epidemiology and morbidity of Epstein-Barr virus infection in pediatric renal transplant recipients: A multicenter, prospective study

Clinical Infectious Diseases

Volumn 56, Issue 1, 2013, Pages 84-92

  Höcker, Britta ^a   Fickenscher, Helmut ^a,b   Delecluse, Henri Jacques ^c   Böhm, Stephan ^a,d   Küsters, Uta ^a   Schnitzler, Paul ^a   Pohl, Martin ^e   John, Ulrike ^f   Kemper, Markus J ^g   Fehrenbach, Henry ^h   Wigger, Marianne ⁱ   Holder, Martin ^j   Schröder, Monika ^k   Billing, Heiko ^a   Fichtner, Alexander ^a   Feneberg, Reinhard ^a   Sander, Anja ^l   Köpf Shakib, Sabine ^a   Süsal, Caner ^m   Tönshoff, Burkhard ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^e UNIVERSITY OF FREIBURG   (Germany)

^f JENA UNIVERSITY HOSPITAL   (Germany)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^h Children's Hospital   (Germany)

ⁱ ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^j Olga Children's Hospital   (Germany)

^k Clementine Kinderhospital   (Germany)

^l Institute of Medical Biometry and Informatics   (Germany)

^m UNIVERSITY OF HEIDELBERG   (Germany)

more..

Author keywords

Epstein Barr virus; human leukocyte antigen; immunosuppression; pediatric renal transplantation; post transplant lymphoproliferative disease

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; GANCICLOVIR; HLA DR7 ANTIGEN; HYPERIMMUNE GLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR BLOCKING AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; UNCLASSIFIED DRUG; VALGANCICLOVIR; VIRUS ANTIBODY;

ANTIVIRAL THERAPY; ARTICLE; CHEMOPROPHYLAXIS; CHILD; CYTOMEGALOVIRUS INFECTION; DISEASE DURATION; EPSTEIN BARR VIRUS INFECTION; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MONONUCLEOSIS; MORBIDITY; PEDIATRIC SURGERY; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SCHOOL CHILD; VIRUS LOAD; VIRUS REACTIVATION;

ADOLESCENT; ANALYSIS OF VARIANCE; ANTIVIRAL AGENTS; CHILD; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; GRAFT REJECTION; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MORBIDITY; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TRANSPLANTS; VIRAL LOAD;

EID: 84871189707     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis823     Document Type: Article

References (38)

1. Henle W, Henle G. Seroepidemiology of the virus. In: Epstein MA, Achong BG, eds. The Epstein-Barr virus. Berlin: Springer Verlag, 1979: 61-78.
2. Preiksaitis JK, Keay S. Diagnosis and management of posttransplant lymphoproliferative disorder in solid-organ transplant recipients. Clin Infect Dis 2001; 33(suppl 1):S38-46.
3. Preiksaitis JK. New developments in the diagnosis and management of posttransplantation lymphoproliferative disorders in solid organ transplant recipients. Clin Infect Dis 2004; 39:1016-23.
4. Dolcetti R. B lymphocytes and Epstein-Barr virus: the lesson of posttransplant lymphoproliferative disorders. Autoimmun Rev 2007; 7:96-101.
5. Jacobson CA, LaCasce AS. Lymphoma: risk and response after solid organ transplant. Oncology (Williston Park) 2010; 24:936-44.
6. Axelrod DA, Holmes R, Thomas SE, Magee JC. Limitations of EBVPCR monitoring to detect EBV associated post-transplant lymphoproliferative disorder. Pediatr Transplant 2003; 7:223-7.
7. Ishihara M, Tanaka E, Sato T, et al. Epstein-Barr virus load for early detection of lymphoproliferative disorder in pediatric renal transplant recipients. Clin Nephrol 2011; 76:40-8.
8. Tanaka E, Sato T, Ishihara M, et al. Asymptomatic high Epstein-Barr viral load carriage in pediatric renal transplant recipients. Pediatr Transplant 2011; 15:306-13.
9. Shroff R, Trompeter R, Cubitt D, Thaker U, Rees L. Epstein-Barr virus monitoring in paediatric renal transplant recipients. Pediatr Nephrol 2002; 17:770-5.
10. Baudouin V, Dehee A, Pedron-Grossetete B, et al. Relationship between CD8+ T-cell phenotype and function, Epstein-Barr virus load, and clinical outcome in pediatric renal transplant recipients: a prospective study. Transplantation 2004; 77:1706-13.
11. Hocker B, Bohm S, Fickenscher H, et al. (Val-)Ganciclovir prophylaxis reduces Epstein-Barr virus primary infection in pediatric renal transplantation. Transpl Int 2012; 25:723-31.
12. Vasudev B, Hariharan S, Hussain SA, Zhu YR, Bresnahan BA, Cohen EP. BK virus nephritis: risk factors, timing, and outcome in renal transplant recipients. Kidney Int 2005; 68:1834-9.
13. Funch DP, Walker AM, Schneider G, Ziyadeh NJ, Pescovitz MD. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 2005; 5:2894-900.
14. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011; 117:5019-32.
15. Schwartz GJ, Munoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol 2009; 20:629-37.
16. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria-an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3:708-14.
17. Solez K, Colvin RB, Racusen LC, et al. Banff '05 meeting report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7:518-26.
18. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8:753-60.
19. Sis B, Mengel M, Haas M, et al. Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010; 10:464-71.
20. Mytilineos J, Lempert M, Scherer S, Schwarz V, Opelz G. Comparison of serological and DNA PCR-SSP typing results for HLA-A and HLAB in 421 black individuals: a collaborative transplant study report. Hum Immunol 1998; 59:512-7.
21. Green M, Soltys K, Rowe DT, Webber SA, Mazareigos G. Chronic high Epstein-Barr viral load carriage in pediatric liver transplant recipients. Pediatr Transplant 2009; 13:319-23.
22. Bingler MA, Feingold B, Miller SA, et al. Chronic high Epstein-Barr viral load state and risk for late-onset posttransplant lymphoproliferative disease/lymphoma in children. Am J Transplant 2008; 8:442-5.
23. Opelz G, Daniel V, Naujokat C, Dohler B. Epidemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma. Transplantation 2009; 88:962-7.
24. Snow AL, Martinez OM. Epstein-Barr virus: evasive maneuvers in the development of PTLD. Am J Transplant 2007; 7:271-7.
25. Siemer D, Kurth J, Lang S, Lehnerdt G, Stanelle J, Kuppers R. EBV transformation overrides gene expression patterns of B cell differentiation stages. Mol Immunol 2008; 45:3133-41.
26. Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol 2001; 1:75-82.
27. Mautner J, Bornkamm GW. The role of virus-specific CD4+ T cells in the control of Epstein-Barr virus infection. Eur J Cell Biol 2012; 91:31-5.
28. Subklewe M, Marquis R, Choquet S, et al. Association of human leukocyte antigen haplotypes with posttransplant lymphoproliferative disease after solid organ transplantation. Transplantation 2006; 82:1093-100.
29. Allen U, Alfieri C, Preiksaitis J, et al. Epstein-Barr virus infection in transplant recipients: summary of a workshop on surveillance, prevention and treatment. Can J Infect Dis 2002; 13:89-99.
30. Preiksaitis JK, Diaz-Mitoma F, Mirzayans F, Roberts S, Tyrrell DL. Quantitative oropharyngeal Epstein-Barr virus shedding in renal and cardiac transplant recipients: relationship to immunosuppressive therapy, serologic responses, and the risk of posttransplant lymphoproliferative disorder. J Infect Dis 1992; 166:986-94.
31. Silins SL, Sherritt MA, Silleri JM, et al. Asymptomatic primary Epstein-Barr virus infection occurs in the absence of blood T-cell repertoire perturbations despite high levels of systemic viral load. Blood 2001; 98:3739-44.
32. Moss DJ, Burrows SR, Khanna R. EBV: immunobiology and host response. In: Arvin A, Campadelli-Fiume G, Mocarski E, et al, eds. Human herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge: Cambridge University Press, 2007: chapter 51.
33. Alfieri C, Allison AC, Kieff E. Effect of mycophenolic acid on Epstein-Barr virus infection of human B lymphocytes. Antimicrob Agents Chemother 1994; 38:126-9.
34. Neyts J, Andrei G, De Clercq E. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo. Antimicrob Agents Chemother 1998; 42:216-22.
35. Doesch AO, Konstandin M, Celik S, et al. Epstein-Barr virus load in whole blood is associated with immunosuppression, but not with post-transplant lymphoproliferative disease in stable adult heart transplant patients. Transpl Int 2008; 21:963-71.
36. Nikiforow S, Bottomly K, Miller G, Munz C. Cytolytic CD4(+)-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation. J Virol 2003; 77:12088-104.
37. Kruger S, Schroers R, Rooney CM, Gahn B, Chen SY. Identification of a naturally processed HLA-DR-restricted T-helper epitope in Epstein-Barr virus nuclear antigen type 1. J Immunother 2003; 26:212-21.
38. Smith JM, Corey L, Bittner R, et al. Subclinical viremia increases risk for chronic allograft injury in pediatric renal transplantation. J Am Soc Nephrol 2010; 21:1579-86.